VKH
TBPH icon

Virtu KCG Holdings’s Theravance Biopharma TBPH Stock Holding History

Virtu KCG Holdings’s Portfolio TBPH Stock Details TBPH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q2 		$742K Buy
+18,629
New +$716K 0.02% 809
2015
Q1 		– Sell
-11,247
Closed -$168K – 3847
2014
Q4 		$168K Buy
+11,247
New +$196K ﹤0.01% 2988

Other funds holding TBPH

WIM
Woodford Investment Management London, United Kingdom $310M AUM 17.41% 1-Year Est. Return
BG
Baupost Group Boston, Massachusetts $5.12B AUM 15.99% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
First Manhattan
First Manhattan New York $36.1B AUM 11.5% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $935B AUM

Virtu KCG Holdings's TBPH Position: Q2 2017 in Review

Virtu KCG Holdings opened a new position in Theravance Biopharma (TBPH) in Q2 2017: 18,629 shares worth $742K. The stake represents 0.02% of the portfolio and ranks #809 among its holdings. This is a return to the name: Virtu KCG Holdings previously reported a position in TBPH as recently as Q4 2014.

Virtu KCG Holdings first reported a position in TBPH in Q4 2014 and has held it in 2 quarters since. 94 funds tracked by Wall St. Rank hold TBPH as of Q2 2017.

  • Virtu KCG Holdings held 18,629 shares of Theravance Biopharma worth $742K as of Q2 2017.
  • Theravance Biopharma was a new Virtu KCG Holdings position in Q2 2017.
  • Theravance Biopharma made up 0.02% of Virtu KCG Holdings's portfolio in Q2 2017, its #809 holding.
  • Virtu KCG Holdings first reported a position in Theravance Biopharma in Q4 2014 and has held it in 2 quarters since.
  • 94 funds tracked by Wall St. Rank held Theravance Biopharma as of Q2 2017.

Based on Virtu KCG Holdings's 13F filing for Q2 2017, filed 11 Aug 2017.